Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Dollar and Under Sleeper Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Turn Around Picks who wrote (7620)	2/16/1999 10:33:00 AM
From: Mr Metals	Read Replies (1) \| Respond to of 8835

Buying NWCM because This stock has principals that purchased over $4 million worth of shares at $10. It has a float of 1.6 mil and 25% of that is shorted!!! Its 52 week high is $17 and some folks feel it can go to $10/share.. The stock is NWCM and is trading at 1 1/32 x 1 1/8. MM

To: Turn Around Picks who wrote (7620)	2/16/1999 1:12:00 PM
From: Micro-Selector	Read Replies (1) \| Respond to of 8835

* SYBD NEWS OUT * (NOTE: Once this patent is received, SYBD will finally have its trio of biotech products ready for the clinical trial stage. This is a critical breakthrough period in SYBD's corporate history. Please see Website for further details.) --- TODAY'S NEWS --- 02/16 09:59 Synthetic Blood International Inc. Announces U.S. Patent Office Allowance of Glucose Biosensor Patent Claims KETTERING, Ohio--(BUSINESS WIRE)--Feb. 16, 1999--Synthetic Blood International Inc. (OTCBB:SYBD) announced today that the U.S. patent office has issued a notice allowing all claims in a new patent application covering the company's implantable glucose biosensor. The patent is expected to be issued soon. The patent application, "Glucose Sensor," covers the company's proprietary glucose biosensor system. In particular, it protects the membrane-enzyme complex that regulates the availability of glucose which permits accurate measurement of glucose levels with low ambient oxygen tension. "Intellectual property is the most important asset a biomedical research and development company such as ours can have," said Robert Nicora, president. "We are pleased to be able to add this important patent to the company's growing patent portfolio." The biosensor system is being developed for use in diabetic patients to continuously monitor blood glucose levels. The patent is the fourth announced by SYBD in the past month. SYBD is also developing Oxycyte(TM), a perfluorocarbon based blood substitute, and Fluorovent(TM), a perfluorocarbon liquid ventilation product. Synthetic Blood International is located in Kettering, Ohio, with West Coast offices and laboratories in Newport Beach, Calif. The company's stock is traded on the OTC Electronic Bulletin Board, symbol SYBD. The company's Web site is sybd.com and e-mail address is sybd@siscom.net. CONTACT: Synthetic Blood International Inc. Joan Mahan, 800/809-6054 Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com (c) 1998 Business Wire